Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

ATEM Capital

Investor type Venture Capital
Founders Anton Gopka

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 2
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 2
Rounds per year 0.25
Lead investments 0
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Data Storage
  • Semiconductor
  • Electronics
  • Clinical Trials
  • Biotechnology

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Density Ventures Canada, Ontario, Toronto
Eir Partners -
FINANCIERE FONDS PRIVES France, Ile-de-France, Paris
Fucheng Touzi China, Guangdong Province, Guangzhou City
Hemeria France, Ile-de-France, Paris
Hongshi Capital Management Beijing, Beijing, China
Horizons Labs -
Inglewood Ventures California, San Diego, United States
IONIQ Berlin, Berlin, Germany
Koffler Group -
Kubera Partners Garden City, New York, United States
Redmile Group California, San Francisco, United States
SAT Capital -
Shenzhen Qianhai Wanrong Hongtu Investment Fund China, Guangdong, Shenzhen
Western Union Accelerator Powered by Techstars Colorado, Denver, United States
Wieland Capital Bayern, Germany, München
Zhengu Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Triumvira Immunologics

Biotechnology
Clinical Trials
Health Care
$45M17 Mar 2022 Austin, Texas, United States

Iridia

Data Storage
Electronics
Semiconductor
$24M16 Mar 2021 Carlsbad, California, United States
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ATEM Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: